Maxime Dely: Therapeutic Apheresis – How Do You Know When You Can’t Wait Any Longer?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Therapeutic Apheresis: How do you know when you can’t wait any longer?
3 clinical criteria to decide on Therapeutic Apheresis
Therapeutic apheresis is neither an automatic reflex nor a last-resort treatment by default. The right indication relies on a structured clinical reasoning, which can be summarized into three key criteria.
1. A clearly identifiable circulating pathogenic target
Apheresis makes sense when the disease mechanism involves a blood-borne factor that can be mechanically removed:
– autoantibodies (TTP, myasthenia gravis, Goodpasture syndrome)
– immune complexes (severe lupus)
– abnormal cells (leukostasis in acute leukemias)
– lipoproteins (homozygous familial hypercholesterolemia)
Without a clearly identified circulating target, the expected benefit becomes questionable.
2. Acute or rapidly progressive clinical severity
Myasthenic crisis with respiratory failure, thrombotic thrombocytopenic purpura, progressive Guillain–Barré syndrome, antibody-mediated graft rejection…
In these situations, apheresis is a life-saving or organ-saving emergency intervention.
3. A mismatch between clinical urgency and the onset of action of standard therapies
Immunosuppressive drugs, IVIg, or chemotherapy may be effective — but sometimes too slow.
Therapeutic apheresis allows an immediate reduction of the pathogenic burden, stabilizing the patient and creating a therapeutic window.
Deciding on apheresis is not about ticking boxes on a list of indications. It is about integrating pathophysiology, clinical severity, and timing, through close multidisciplinary collaboration.
When properly indicated, apheresis is not a technical luxury — it is a strategic clinical tool.”
Find more posts featuring Maxime Dely on Hemostasis Today.
-
Apr 8, 2026, 07:32Giulia Simini: Acquired von Willebrand Syndrome and Coagulation Abnormalities in MPN-Associated Thrombocytosis
-
Apr 8, 2026, 07:14Julian Kyoung-Ryul Chun: Join the Discussion at EHRA 2026
-
Apr 8, 2026, 06:41Stephanie Diez de Sollano: Why Ehlers-Danlos Syndrome Deserves More Attention
-
Apr 7, 2026, 19:17Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
-
Apr 7, 2026, 19:07Clara Meijs: Great Time Presenting Our Endometriosis Project at the AHA EPI Lifestyle Conference
-
Apr 7, 2026, 18:18Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
-
Apr 7, 2026, 17:44Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine
-
Apr 7, 2026, 17:35Nikola Grubor: In Situ Pulmonary Arterial Thrombosis Mimicking CTEPH in Eisenmenger
-
Apr 7, 2026, 17:34Pooja Choradia: vWF Breakdown in Aortic Stenosis – Anaemia and Pulmonary Relevance